Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension

American Journal of Hypertension

Volumn 11, Issue 4 I, 1998, Pages 462-470

  Pool, James L ^a   Guthrie, Robert M ^b   Littlejohn III, Thomas W ^c   Raskin, Philip ^d   Shephard, Alexander M M ^e   Weber, Michael A ^f   Weir, Matthew R ^g   Wilson, Thomas W ^h   Wright, James ⁱ   Kassler Taub, Kenneth B ^j   Reeves, Richard A ^j  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Piedmont Medical Research Associates   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Memorial Research Medical Clinic   (United States)

^g UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^h ROYAL UNIVERSITY HOSPITAL   (Canada)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Angiotensin II receptor antagonist; Drug withdrawal; Hypertension; Irbesartan; Plasma renin activity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; IRBESARTAN; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031748816     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00501-3     Document Type: Article

References (18)

1. 1 receptor antagonist irbesartan in hypertension. Hypertension. 25:1995;22-29.
2. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 265:1993;826-834.
3. Necciari J, Denolle T, Le Coz F, et al. Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man (abst). J Hypertens. 12:1994;88.
4. Sissmann J, Bouroudian M, Armagnac C, et al. Angiotensin II blockade in healthy volunteers tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295) (abst) . J Hypertens. 12:1994;S92.
5. Ribstein J, Sissmann J, Picard A, et al. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects (abst). J Hypertens. 12:1994;131.
6. Lalonde RL. Pharmacokinetic-pharmacodynamic relationships of cardiovascular drugs. Derendorf H, Hochhaus G. Handbook of Pharmacokinetic/Pharmacodynamic Correlation. 1995;197-225 CRC Press, Boca Raton, FL.
7. Sumner DJ, Phil D, Elliott HL, Reid JL. Analysis of the pressor dose response. Clin Pharmacol Ther. 32:1982;450-458.
8. Wong CM, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
9. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context . Lancet. 335:1990;827-838.
10. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 17:1995;911-923.
11. Ruilope LM, Simpson RL, Toh J, et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Pressure. 5:1996;32-40.
12. Kaplan NM. Treatment of hypertension drug therapy . Kaplan NM. Clinical Hypertension. 1994;191-280 Williams & Wilkins, Baltimore.
13. Donnelly R, Meredith PA, Elliott HL, Reid JL. Kinetic-dynamic relations and individual responses to enalapril. Hypertension. 15:1990;301-309.
14. Simon SR, Black HR, Moser M, Berland WE. Cough and ACE inhibitors. Arch Intern Med. 152:1992;1698-1700.
15. de Bruijn B, Cocco G, Tyler HM. Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension. J Cardiovasc Pharmacol. 12:(suppl 7):1988;S107-S109.
16. Chan JCN, Critchley JAJH, Lappe JT, et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens. 9:1995;765-771.
17. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 75:1995;793-795.
18. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure (JNC VI). Arch Intern Med. 157:1997;2413-2446.